MARLBOROUGH, Mass. / Jan 02, 2024 / Business Wire / Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 1:30 p.m. Pacific Time.
The presentation and Q&A session will be webcast live and may be accessed through a link on the Investors section of Hologic’s website at http://investors.hologic.com. The webcast will be available for 30 days following the event.
About Hologic, Inc.
Hologic, Inc. is an innovative medical technology company primarily focused on improving women’s health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com.
| Last Trade: | US$73.99 |
| Daily Change: | 0.10 0.14 |
| Daily Volume: | 5,119,428 |
| Market Cap: | US$16.460B |
October 21, 2025 October 02, 2025 September 26, 2025 September 03, 2025 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
